Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on ACADIA Pharmaceuticals and raised the price target to $35 from the previous $32. The adjustment reflects an updated valuation outlook for the NASDAQ-listed company.

Rating and Target Details

The research note reinforces a positive stance on the stock, citing the revised price target as a key indicator of potential upside. The table below summarizes the changes:

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol ACAD.

Acadia Pharmaceuticals Inc. shares rose significantly on Friday after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide). The therapy is intended for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved by the European Commission, DAYBU would become the first therapy specifically authorized for this indication in the European Union. The stock movement occurred during a session where the health care sector gained approximately 2.76%, while the broader S&P 500 remained flat.

The CHMP’s positive opinion follows a re-examination procedure, reversing a negative vote issued in February. The recommendation is primarily based on results from the Phase 3 LAVENDER study. This study demonstrated statistically significant and clinically meaningful improvements in core features of Rett syndrome, as measured by the Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I) scale. These findings indicate that treatment with DAYBU can address some of the most impactful aspects of Rett syndrome, which severely impact quality of life for patients and caregivers.

Catherine Owen Adams, Acadia’s Chief Executive Officer, highlighted the significance of the milestone, noting the lack of approved therapies in the EU for the neurobehavioral symptoms of this condition. She emphasized the company's commitment to addressing the unmet needs of patients and caregivers. Pedro Rocha, President of Rett Syndrome Europe, welcomed the opinion, stating it represents hope for thousands of individuals and families affected by the condition.

Following the recommendation, the European Commission will review the opinion and is expected to issue a final decision in the coming months. If granted, the marketing authorization would apply to all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. Acadia Pharmaceuticals is currently trading at $26.57, significantly above its 20-day simple moving average (SMA) of $22.02, indicating strong short-term momentum. The stock is 23.1% above its 20-day SMA, although the relative strength index (RSI) is at 82.37, suggesting the stock is in overbought territory.

Technical Analysis and Market Position

The stock's current price is nearing key resistance at $28. While the 50-day SMA is below the current price, the 50-day SMA recently crossed below the 200-day SMA in March, marking a death cross which could signal caution for longer-term investors. According to Benzinga Edge scorecard data, Acadia Pharmaceuticals holds a Value score of 63.15, indicating it is reasonably valued relative to peers, but a Momentum score of 29.67, showing underperformance compared to the broader market.